ALLMedicine™ Advanced Prostate Cancer Center
Research & Reviews 3,445 results
https://doi.org/10.1007/s12094-021-02561-5 10.3322/caac.21492 10.1007/s12094-017-1823-y 10.1086/321805 10.1016/j.cell.2015.05.001 10.1038/nrurol.2016.212 10.1001/jamaoncol.2015.1341 10.1016/j.ejca.2019.05.007 10.1200/JCO.2017.35.15_suppl.5005 10.1016/j.ccr.2011.04.008 10.1016/j.eururo.2014.10.027 10.1200/PO.19.00345 10.1200/JCO.2012.43.1882 10.1016/j.eururo.2015.11.022 10.1056/NEJMoa1506859 10.1001/jamaoncol.2018.5801 10.1200/JCO.2012.44.1238 10.1158/1078-0432.CCR-18-1912 10.1158/1078-0432.CCR-08-0872 10.1200/JCO.2014.55.3487 10.1016/S0140-6736(00)02163-2 10.1002/14651858.CD003506.pub2 10.1200/JCO.2012.46.5492 10.1056/NEJMoa1212299 10.1056/NEJMoa1503747 10.1200/JCO.2017.75.3657 10.1016/S0140-6736(15)01037-5 10.1016/S1470-2045(12)70560-0 10.1016/j.eururo.2015.09.013 10.1056/NEJMoa1704174 10.1016/S1470-2045(19)30082-8 10.1056/NEJMoa1702900 10.1200/JCO.19.00799 10.1056/NEJMoa1903835 10.1016/j.eururo.2017.10.002 10.1016/j.ejca.2018.08.010 10.1016/j.eururo.2019.09.004 10.1097/JU.0000000000000636 10.1016/j.eururo.2018.09.008 10.1016/S0140-6736(18)32486-3 10.1200/JCO.2007.12.4487 10.1111/j.1464-410X.2005.05798.x 10.1200/JCO.2017.35.15_suppl.5027 10.1200/JCO.2015.64.2702 10.1016/j.urology.2013.10.026 10.1016/j.eururo.2019.01.049 10.1007/s00345-014-1406-2 10.1056/NEJMoa1800536 10.1056/NEJMoa1715546 10.1056/NEJMoa1815671 10.1200/JCO.2020.38.15_suppl.5515 10.1200/JCO.2020.38.15_suppl.5514 10.1056/NEJMoa040720 10.1056/NEJMoa1209096 10.1056/NEJMoa1405095 10.1056/NEJMoa1014618 10.1056/NEJMoa1207506 10.1016/S0140-6736(10)61389-X 10.1200/JCO.2018.77.9827 10.1016/j.eururo.2017.07.035 10.1056/NEJMoa1911206 10.1056/NEJMoa1213755 10.1200/JCO.2017.77.6880 10.1158/1078-0432.CCR-13-3309 10.1158/1078-0432.CCR-15-1259 10.1158/1078-0432.CCR-12-3791 10.1016/S1470-2045(19)30408-5 10.1097/PPO.0000000000000219 10.1093/annonc/mdz192 10.1056/NEJMoa2022485 10.1056/NEJMoa1911440 10.1200/PO.19.00346 10.1056/NEJMoa1001294 10.2967/jnumed.117.199570 10.1158/1078-0432.CCR-15-0820 10.1016/S1470-2045(18)30198-0 10.1056/NEJMoa1603144 10.1200/JCO.18.00358 10.1016/j.eururo.2020.01.012 10.1200/JCO.20.00046
Clinical & Translational Oncology : Official Publication ... González Del Alba A, Méndez-Vidal MJ et. al.
Feb 24th, 2021 - The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanc...
https://doi.org/10.1038/s41391-021-00337-0 10.1200/JCO.2004.06.037 10.3389/fonc.2019.00801 10.1210/er.2002-0032 10.1002/jcb.10757 10.1038/35094009 10.1200/JCO.1993.11.8.1566 10.1007/s00345-014-1288-3 10.1016/S0022-5347(17)35646-X 10.1016/j.ijsu.2010.02.007 10.18637/jss.v036.i03 10.1200/jco.2015.33.7_suppl.240 10.1200/jco.2013.31.6_suppl.89 10.1016/j.clgc.2017.08.017 10.1002/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T 10.1016/S0002-9343(99)80323-4 10.1111/bju.12826 10.1016/S0090-4295(98)00354-9 10.21873/anticanres.12702 10.1002/cncr.23473 10.1016/j.urology.2013.07.029 10.1016/S0022-5347(01)66468-1 10.1007/s12032-013-0647-z 10.1126/science.1168175 10.1159/000499276 10.1158/0008-5472.CAN-11-3980 10.4103/1008-682X.133314 10.1016/0960-0760(92)90401-4 10.1016/j.eururo.2013.10.035 10.1186/1756-8722-1-21 10.1530/ERC-17-0355 10.1200/jco.2008.26.15_suppl.16116 10.3892/mco.2016.817 10.1016/S0302-2838(02)00051-9 10.1016/S0022-5347(01)64846-8 10.1111/iju.13234
Prostate Cancer and Prostatic Diseases; Soo A, O'Callaghan ME et. al.
Feb 19th, 2021 - Antiandrogen withdrawal (AAW) response is the paradoxical decrease in prostate-specific antigen (PSA) following the withdrawal of antiandrogen in patients with advanced prostate cancer. Currently, the reported literature on the proportion of patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891168
BMC Urology; Wu Y, Chen X et. al.
Feb 18th, 2021 - A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We ...
https://www.ncbi.nlm.nih.gov/pubmed/33596192
Clinical Advances in Hematology & Oncology : H&O; Khanna A, O'Connor LP et. al.
Feb 17th, 2021 - Recent population-based studies suggest that the incidence of advanced and metastatic prostate cancer may be increasing. Concurrently with this apparent stage migration toward advanced disease, several major developments have occurred in the treat...
https://doi.org/10.1007/s00345-021-03618-4 10.1007/s00345-020-03265-1 10.1007/s00345-020-03433-3 10.1056/NEJMoa2004325 10.1007/s00345-019-03063-4 10.1007/s00345-020-03296-8 10.1007/s00345-019-03060-7 10.1007/s00345-019-02997-z 10.1007/s00345-020-03098-y
World Journal of Urology; Hupe MC, Merseburger AS
Feb 16th, 2021 - Advanced prostate cancer.|2021|Hupe MC,Merseburger AS,|
Guidelines 21 results
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,
Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB
Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.
Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...
Drugs 15 results see all →
Clinicaltrials.gov 3,953 results
https://doi.org/10.1007/s12094-021-02561-5 10.3322/caac.21492 10.1007/s12094-017-1823-y 10.1086/321805 10.1016/j.cell.2015.05.001 10.1038/nrurol.2016.212 10.1001/jamaoncol.2015.1341 10.1016/j.ejca.2019.05.007 10.1200/JCO.2017.35.15_suppl.5005 10.1016/j.ccr.2011.04.008 10.1016/j.eururo.2014.10.027 10.1200/PO.19.00345 10.1200/JCO.2012.43.1882 10.1016/j.eururo.2015.11.022 10.1056/NEJMoa1506859 10.1001/jamaoncol.2018.5801 10.1200/JCO.2012.44.1238 10.1158/1078-0432.CCR-18-1912 10.1158/1078-0432.CCR-08-0872 10.1200/JCO.2014.55.3487 10.1016/S0140-6736(00)02163-2 10.1002/14651858.CD003506.pub2 10.1200/JCO.2012.46.5492 10.1056/NEJMoa1212299 10.1056/NEJMoa1503747 10.1200/JCO.2017.75.3657 10.1016/S0140-6736(15)01037-5 10.1016/S1470-2045(12)70560-0 10.1016/j.eururo.2015.09.013 10.1056/NEJMoa1704174 10.1016/S1470-2045(19)30082-8 10.1056/NEJMoa1702900 10.1200/JCO.19.00799 10.1056/NEJMoa1903835 10.1016/j.eururo.2017.10.002 10.1016/j.ejca.2018.08.010 10.1016/j.eururo.2019.09.004 10.1097/JU.0000000000000636 10.1016/j.eururo.2018.09.008 10.1016/S0140-6736(18)32486-3 10.1200/JCO.2007.12.4487 10.1111/j.1464-410X.2005.05798.x 10.1200/JCO.2017.35.15_suppl.5027 10.1200/JCO.2015.64.2702 10.1016/j.urology.2013.10.026 10.1016/j.eururo.2019.01.049 10.1007/s00345-014-1406-2 10.1056/NEJMoa1800536 10.1056/NEJMoa1715546 10.1056/NEJMoa1815671 10.1200/JCO.2020.38.15_suppl.5515 10.1200/JCO.2020.38.15_suppl.5514 10.1056/NEJMoa040720 10.1056/NEJMoa1209096 10.1056/NEJMoa1405095 10.1056/NEJMoa1014618 10.1056/NEJMoa1207506 10.1016/S0140-6736(10)61389-X 10.1200/JCO.2018.77.9827 10.1016/j.eururo.2017.07.035 10.1056/NEJMoa1911206 10.1056/NEJMoa1213755 10.1200/JCO.2017.77.6880 10.1158/1078-0432.CCR-13-3309 10.1158/1078-0432.CCR-15-1259 10.1158/1078-0432.CCR-12-3791 10.1016/S1470-2045(19)30408-5 10.1097/PPO.0000000000000219 10.1093/annonc/mdz192 10.1056/NEJMoa2022485 10.1056/NEJMoa1911440 10.1200/PO.19.00346 10.1056/NEJMoa1001294 10.2967/jnumed.117.199570 10.1158/1078-0432.CCR-15-0820 10.1016/S1470-2045(18)30198-0 10.1056/NEJMoa1603144 10.1200/JCO.18.00358 10.1016/j.eururo.2020.01.012 10.1200/JCO.20.00046
Clinical & Translational Oncology : Official Publication ... González Del Alba A, Méndez-Vidal MJ et. al.
Feb 24th, 2021 - The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanc...
https://doi.org/10.1038/s41391-021-00337-0 10.1200/JCO.2004.06.037 10.3389/fonc.2019.00801 10.1210/er.2002-0032 10.1002/jcb.10757 10.1038/35094009 10.1200/JCO.1993.11.8.1566 10.1007/s00345-014-1288-3 10.1016/S0022-5347(17)35646-X 10.1016/j.ijsu.2010.02.007 10.18637/jss.v036.i03 10.1200/jco.2015.33.7_suppl.240 10.1200/jco.2013.31.6_suppl.89 10.1016/j.clgc.2017.08.017 10.1002/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T 10.1016/S0002-9343(99)80323-4 10.1111/bju.12826 10.1016/S0090-4295(98)00354-9 10.21873/anticanres.12702 10.1002/cncr.23473 10.1016/j.urology.2013.07.029 10.1016/S0022-5347(01)66468-1 10.1007/s12032-013-0647-z 10.1126/science.1168175 10.1159/000499276 10.1158/0008-5472.CAN-11-3980 10.4103/1008-682X.133314 10.1016/0960-0760(92)90401-4 10.1016/j.eururo.2013.10.035 10.1186/1756-8722-1-21 10.1530/ERC-17-0355 10.1200/jco.2008.26.15_suppl.16116 10.3892/mco.2016.817 10.1016/S0302-2838(02)00051-9 10.1016/S0022-5347(01)64846-8 10.1111/iju.13234
Prostate Cancer and Prostatic Diseases; Soo A, O'Callaghan ME et. al.
Feb 19th, 2021 - Antiandrogen withdrawal (AAW) response is the paradoxical decrease in prostate-specific antigen (PSA) following the withdrawal of antiandrogen in patients with advanced prostate cancer. Currently, the reported literature on the proportion of patie...
https://www.medscape.com/viewarticle/946111
Feb 18th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in PLoS One, tested the clinical fea...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891168
BMC Urology; Wu Y, Chen X et. al.
Feb 18th, 2021 - A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We ...
https://www.ncbi.nlm.nih.gov/pubmed/33596192
Clinical Advances in Hematology & Oncology : H&O; Khanna A, O'Connor LP et. al.
Feb 17th, 2021 - Recent population-based studies suggest that the incidence of advanced and metastatic prostate cancer may be increasing. Concurrently with this apparent stage migration toward advanced disease, several major developments have occurred in the treat...
News 437 results
https://www.medscape.com/viewarticle/946111
Feb 18th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in PLoS One, tested the clinical fea...
https://www.medscape.com/viewarticle/945995
Feb 17th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...
https://www.medscape.com/viewarticle/943903
Jan 10th, 2021 - Irradiating the whole pelvis rather than just the prostate reduces the likelihood of recurrence in men with high-risk locally advanced prostate cancer, according to a randomized controlled trial. Results from the trial, called POP-RT, were reporte...
https://www.medscape.com/viewarticle/942933
Dec 17th, 2020 - The US Food and Drug Administration (FDA) today approved an oral form of androgen deprivation therapy (ADT) known as relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. Relugolix is an oral gonadotropin-releasing...
https://www.staging.medscape.com/viewarticle/940590
Nov 8th, 2020 - The first and only immunotherapy product for advanced cancer, sipuleucel-T (Provenge), has not been widely used clinically since its launch 10 years ago, and has been largely eclipsed by two drugs launched since then — the androgen-receptor signal...
